| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
24024 |
| Drug |
Tirzepatide |
| Brand |
(Mounjaro®) |
| Indication |
For chronic weight management, including weight loss and weight maintenance, in adults with an initial body mass index of: ≥30 kg/m2, or ≥27 kg/m2 to <30 kg/m2 in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus). |
| Rapid review commissioned |
24/06/2024 |
| Rapid review completed |
30/07/2024 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical and cost effectiveness of tirzepatide for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
27/08/2024 |
| Pre-submission consultation with Applicant |
15/10/2024 |
| Full submission received from Applicant |
10/04/2025 |
| Preliminary review sent to Applicant |
20/06/2025 |
| NCPE assessment re-commenced |
21/07/2025 |
| Follow-up to preliminary review sent to Applicant |
01/08/2025 |
| NCPE assessment re-commenced |
08/08/2025 |
| Factual accuracy sent to Applicant |
04/11/2025 |
